More Ranbaxy woes

The FDA has put Ranbaxy Laboratories on notice.


Bloomberg reports that the US regulator says a recent inspection shows a Punjab, India, plant that makes 60% to 70% of the company's active ingredients is failing to make the grade.

The company agreed to shell out $500 million over fraud allegations in May, and Bloomberg notes that the US has already banned items from three Ranbaxy plants from entering the country.

You must be a registered member of MMM to post a comment.

Next Article in Channel